Published in Invest Ophthalmol Vis Sci on September 01, 2002
Effect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection. J Virol (2003) 1.33
Viral infection of the lungs through the eye. J Virol (2006) 1.05
NF-κB is the transcription factor for FGF-2 that causes endothelial mesenchymal transformation in cornea. Invest Ophthalmol Vis Sci (2012) 0.94
Strategies for local gene therapy of corneal allograft rejection. Middle East Afr J Ophthalmol (2013) 0.94
Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjögren's syndrome. Lab Invest (2012) 0.90
Common and distinct pathways for cellular activities in FGF-2 signaling induced by IL-1beta in corneal endothelial cells. Invest Ophthalmol Vis Sci (2009) 0.89
Induction of FGF-2 synthesis by IL-1beta in aqueous humor through P13-kinase and p38 in rabbit corneal endothelium. Invest Ophthalmol Vis Sci (2009) 0.85
Interleukin-1β enhances cell migration through AP-1 and NF-κB pathway-dependent FGF2 expression in human corneal endothelial cells. Biol Cell (2013) 0.83
Interleukin-1β-induced Wnt5a enhances human corneal endothelial cell migration through regulation of Cdc42 and RhoA. Mol Cell Biol (2014) 0.83
Systematic assessment of microneedle injection into the mouse cornea. Eur J Med Res (2012) 0.75
WNT10B Enhances Proliferation through β-Catenin and RAC1 GTPase in Human Corneal Endothelial Cells. J Biol Chem (2015) 0.75
Active Pedicle Epithelial Flap Transposition Combined with Amniotic Membrane Transplantation for Treatment of Nonhealing Corneal Ulcers. J Ophthalmol (2016) 0.75
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J (2004) 5.33
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov (2006) 4.03
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology (2005) 3.20
Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. J Exp Med (2008) 3.08
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J (2002) 2.90
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology (2011) 2.65
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol (2002) 2.57
Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006) 2.52
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci (2002) 2.45
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med (2003) 2.39
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg? Ophthalmology (2005) 2.22
Residual bed thickness and corneal forward shift after laser in situ keratomileusis. J Cataract Refract Surg (2004) 2.21
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci (2003) 2.09
Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med (2014) 2.02
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol (2005) 1.97
Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest (2002) 1.95
CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol (2007) 1.83
Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol (2002) 1.68
MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest (2004) 1.65
Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J (2002) 1.63
Microbial keratitis following corneal transplantation. Am J Ophthalmol (2006) 1.58
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol (2002) 1.57
Descemet stripping automated endothelial keratoplasty in a child. J AAPOS (2008) 1.50
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J Immunol (2008) 1.42
The integrin family of cell adhesion molecules has multiple functions within the CNS. J Neurosci Res (2002) 1.41
Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors. Ann Neurol (2005) 1.41
Oculocardiac reflex caused by contact lenses. Ophthalmic Physiol Opt (2003) 1.40
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol (2004) 1.39
Inadvertent insertion of an opposite-power intraocular lens. J Cataract Refract Surg (2006) 1.38
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci (2007) 1.38
Inducible production of interferon-gamma in the developing brain causes cerebellar dysplasia with activation of the Sonic hedgehog pathway. Mol Cell Neurosci (2004) 1.36
Interferon-gamma induced medulloblastoma in the developing cerebellum. J Neurosci (2004) 1.35
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci (2007) 1.32
The stromal cell-derived factor-1alpha/CXCR4 ligand-receptor axis is critical for progenitor survival and migration in the pancreas. J Cell Biol (2003) 1.31
Replication of TCF4 through association and linkage studies in late-onset Fuchs endothelial corneal dystrophy. PLoS One (2011) 1.30
The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci (2003) 1.28
The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res (2004) 1.26
Trends in the indications for penetrating keratoplasty, 1980-2001. Cornea (2005) 1.25
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci (2006) 1.22
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci (2003) 1.22
Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J Neurosci Res (2003) 1.22
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes (2003) 1.21
Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol (2004) 1.21
Innate STAT1-dependent genomic response of neurons to the antiviral cytokine alpha interferon. J Virol (2005) 1.21
Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. Microcirculation (2007) 1.19
VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci (2003) 1.17
Refractive change after descemet stripping automated endothelial keratoplasty surgery and its correlation with graft thickness and diameter. Cornea (2009) 1.17
The effectiveness of isobutyl cyanoacrylate tissue adhesive for the treatment of corneal perforations. Am J Ophthalmol (2005) 1.16
Astrocyte-targeted expression of IL-6 protects the CNS against a focal brain injury. Exp Neurol (2003) 1.16
Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain. J Clin Invest (2003) 1.16
Differential regulation of interferon regulatory factor (IRF)-7 and IRF-9 gene expression in the central nervous system during viral infection. J Virol (2005) 1.15
Developmental regulation of beta1 integrins during angiogenesis in the central nervous system. Mol Cell Neurosci (2002) 1.14
Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol (2006) 1.14
alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol (2006) 1.12
The extracellular matrix and cytokines regulate microglial integrin expression and activation. J Immunol (2003) 1.12
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology (2007) 1.12
Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci (2002) 1.11
Influence of pupil diameter on the relation between ocular higher-order aberration and contrast sensitivity after laser in situ keratomileusis. Invest Ophthalmol Vis Sci (2006) 1.11
Lipocalin 2 in the central nervous system host response to systemic lipopolysaccharide administration. J Neuroinflammation (2011) 1.10
Viral persistence and chronic immunopathology in the adult central nervous system following Coxsackievirus infection during the neonatal period. J Virol (2009) 1.10
Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol Vis (2006) 1.10
Inflammatory monocytes and the pathogenesis of viral encephalitis. J Neuroinflammation (2012) 1.08
Antigenicity of porcine cornea as xenograft. Curr Eye Res (2003) 1.08
Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol (2009) 1.07
Cytokines regulate microglial adhesion to laminin and astrocyte extracellular matrix via protein kinase C-dependent activation of the alpha6beta1 integrin. J Neurosci (2002) 1.07
Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Invest Ophthalmol Vis Sci (2003) 1.07
Two mutations in the TGFBI (BIGH3) gene associated with lattice corneal dystrophy in an extensively studied family. Invest Ophthalmol Vis Sci (2004) 1.06
Risk factors for progression to penetrating keratoplasty in patients with keratoconus. Am J Ophthalmol (2005) 1.05
Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea (2003) 1.05
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol (2009) 1.04
Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur J Immunol (2002) 1.04
Polymorphic corneal amyloidosis: a disorder due to a novel mutation in the transforming growth factor beta-induced (BIGH3) gene. Ophthalmology (2004) 1.04
Cell and agonist-specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells. J Neurochem (2006) 1.03
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol (2007) 1.03
Chemokines are differentially expressed by astrocytes, microglia and inflammatory leukocytes in Toxoplasma encephalitis and critically regulated by interferon-gamma. Acta Neuropathol (2002) 1.03
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci (2003) 1.03
Role of IFN-gamma in an experimental murine model of West Nile virus-induced seizures. J Neurochem (2007) 1.03
Leukocyte infiltration, but not neurodegeneration, in the CNS of transgenic mice with astrocyte production of the CXC chemokine ligand 10. J Immunol (2002) 1.03
STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system. Proc Natl Acad Sci U S A (2002) 1.02